A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Completed · Phase 1

Conditions studied: Acute Myeloid Leukemia

In brief

A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy. The primary purpose of this study was to assess whether siremadlin in combination with venetoclax plus azacitidine can enhance the clinical response in unfit AML participants without unacceptable levels of treatment-emergent toxicities.

Key facts

Study ID

NCT05155709

Run by

Novartis Pharmaceuticals

People needed

14

Starts

2022-05-17

Expected to finish

2024-04-17

Last updated by the study team

2026-05-07

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age at the date of signing the informed consent form (ICF):
• Arm 1 and Arm 2: ≥ 18 years
• Participants diagnosed with AML based on WHO 2016 classification (Arber et al 2016) who are ineligible for standard induction chemotherapy and:
• Arm 1 : have received at least 2 cycles and not more than 4 cycles of first-line venetoclax plus azacitidine treatment and have not achieved a CR, CRi, CRh or MLFS.
• Arm 2 : newly diagnosed AML with adverse genetic risk stratification (according to ELN 2022) (except TP53 mutation positive participants).
• Participant (in both arms) must be considered ineligible for standard of care intensive induction chemotherapy defined by the following:
• 75 years of age; OR
• 18 to 74 years of age with at least one of the following co-morbidities: Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or 3; Cardiac history of congestive heart failure (CHF) requiring treatment or Ejection Fraction ≤ 50% or chronic stable angina; DLCO ≤ 65% or FEV1 ≤ 65%.
• Participants must have an ECOG performance status:
• 0 to 2 for participants ≥ 75 years of age. OR 0 to 3 for participants ≥ 18 to 74 years of age.
• WBC < 25x109/L
• AST and ALT ≤ 3 × ULN
• Estimated Glomerular Filtration Rate (eGFR)≥ 60 mL/min/1.73 m2

You may not qualify if…

• Prior exposure to MDM2-inhibitor therapy at any time.
• Participants with TP53 mutation positive.
• Participants with del17p.
• Participants with AML-M3 / APL (Acute promyelocytic leukemia) with PML-RARA (Promyelocytic leukemia/retinoic acid receptor alpha) or with AML secondary to Down's syndrome.
• Participants treated with FLT3 inhibitors for AML indication are not eligible.
• Participants who require treatment with moderate or strong CYP3A4 inducers within 14 days prior to starting study treatment, or are expected to receive moderate or strong CYP3A4 inducers during the entire study
• Participants who require treatment with substrates of CYP3A4/5 with a narrow therapeutic index.

Where it is running

• Oregon Health Sciences University — Portland, Oregon, United States
• Texas Oncology Sammons Cancer Center — Dallas, Texas, United States
• Novartis Investigative Site — Hong Kong, Hong Kong
• Novartis Investigative Site — Budapest, Hungary
• Novartis Investigative Site — Beersheba, Israel
• Novartis Investigative Site — Jerusalem, Israel
• Novartis Investigative Site — Bologna, BO, Italy
• Novartis Investigative Site — Alor Star, Kedah, Malaysia
• Novartis Investigative Site — Kuala Selangor, Malaysia
• Novartis Investigative Site — Izmir, Balcova, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.